ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, Wunderlich M, Jann JC, Wein A, Altrock E, Demmerle M, Mukherjee S, Ali AM, Rapp F, Nowak V, Weimer N, Obländer J, Palme I, Göl M, Jawhar A, Darwich A, Wuchter P, Weiss C, Raza A, Foulks JM, Starczynowski DT, Yang FC, Metzgeroth G, Steiner L, Jawhar M, Hofmann WK, Nowak D.
Riabov V, et al. Among authors: jann jc.
Haematologica. 2023 Nov 2. doi: 10.3324/haematol.2023.282921. Online ahead of print.
Haematologica. 2023.
PMID: 37916386
Free article.